Wed, Aug 14, 9:04 PM (153 days ago)
On August 14, 2024, Phio Pharmaceuticals Corp. reported its financial results for the quarter ending June 30, 2024. The announcement was made through a Form 8-K filing with the SEC, which included a press release as Exhibit 99.1. The filing indicates that the information will not be treated as "filed" under the Exchange Act, meaning it is not subject to certain liabilities unless explicitly referenced in future filings. The report was signed by Robert Bitterman, the President and CEO, confirming the company's compliance with SEC requirements. The specific financial results, including revenue, expenses, and any significant changes in financial position or stock value, were not detailed in the summary provided. As Phio Pharmaceuticals is listed on the Nasdaq Capital Market under the symbol PHIO, the results may impact investor sentiment and trading activity in the company's shares.